NASDAQ:TALS Talaris Therapeutics (TALS) Stock Price, News & Analysis → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free TALS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.04▼$15.8650-Day Range$12.36▼$28.3652-Week Range$0.89▼$27.95Volume374,283 shsAverage Volume386,531 shsMarket Capitalization$645.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSocial Media Get Talaris Therapeutics alerts: Email Address Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Talaris Therapeutics Stock (NASDAQ:TALS)Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.Read More Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> TALS Stock News HeadlinesFebruary 25, 2024 | benzinga.comLongitude Venture Partners III, L.P.'s Net WorthNovember 1, 2023 | msn.comTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15April 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!October 19, 2023 | msn.comTalaris Therapeutics goes ex-dividend tomorrowOctober 18, 2023 | finanznachrichten.deTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 17, 2023 | msn.comTalaris shareholders approve merger, 1-for-10 reverse stock splitOctober 17, 2023 | finance.yahoo.comTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 6, 2023 | marketwatch.comShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to MergerApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!October 6, 2023 | finance.yahoo.comTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioOctober 4, 2023 | finance.yahoo.comNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsSeptember 12, 2023 | finance.yahoo.comWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateAugust 15, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTAugust 14, 2023 | finance.yahoo.comImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance BusinessAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFJuly 28, 2023 | benzinga.comMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law FirmJuly 27, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)July 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMSJuly 18, 2023 | msn.comTalaris Therapeutics: Cashing Out Ahead Of Tourmaline MergerJuly 6, 2023 | msn.comTalaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75June 27, 2023 | markets.businessinsider.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETIJune 26, 2023 | businesswire.comTALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALSJune 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. MergerJune 23, 2023 | bizjournals.comTalaris Therapeutics announces merger after layoffsJune 22, 2023 | bizjournals.comNY biotech to go public by merging with Boston firm that laid off 95% of staffJune 22, 2023 | msn.comTalaris jumps 29% on merger with Tourmaline Bio in all-stock dealJune 22, 2023 | markets.businessinsider.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIRSee More Headlines Receive TALS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TALS CUSIPN/A CIK1827506 Webtalaristx.com Phone502-398-9250FaxN/AEmployees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.93% Return on Assets-37.37% Debt Debt-to-Equity RatioN/A Current Ratio15.41 Quick Ratio15.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book3.48Miscellaneous Outstanding Shares42,764,000Free Float35,708,000Market Cap$645.31 million OptionableNot Optionable Beta2.18 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Mary Kay Fenton (Age 59)Interim CEO, Pres, CFO & Treasurer Comp: $598.98kDr. Suzanne T. Ildstad M.D. (Age 70)Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director Comp: $318.3kMs. Suzanne TollerudVP of Corp. Devel.Key CompetitorsCabaletta BioNASDAQ:CABAMesoblastNASDAQ:MESOHilleVaxNASDAQ:HLVXStemline TherapeuticsNASDAQ:STMLCullinan OncologyNASDAQ:CGEMView All CompetitorsInsidersSuzanne IldstadSold 12,942 sharesTotal: $32,225.58 ($2.49/share)Suzanne IldstadSold 16,870 sharesTotal: $43,693.30 ($2.59/share)Suzanne IldstadSold 25,419 sharesTotal: $62,530.74 ($2.46/share)Suzanne IldstadSold 75,001 sharesTotal: $179,252.39 ($2.39/share)Suzanne IldstadSold 7,841 sharesTotal: $19,759.32 ($2.52/share)View All Insider Transactions TALS Stock Analysis - Frequently Asked Questions How were Talaris Therapeutics' earnings last quarter? Talaris Therapeutics, Inc. (NASDAQ:TALS) released its earnings results on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics? Talaris Therapeutics announced a dividend on Thursday, October 19th. Stockholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date is Friday, October 20th. Read our dividend analysis for TALS. When did Talaris Therapeutics IPO? Talaris Therapeutics (TALS) raised $150 million in an IPO on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO. This page (NASDAQ:TALS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
